Phase II ARCHER trial showed a significant reduction in left ventricular (LV) mass (p=0.0117) and improvements in multiple key cardiac MRI (CMR) measures of structural heart recovery in patients with ...
Toronto, Ontario--(Newsfile Corp. - September 24, 2024) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage life sciences company focused on the ...
inflammatory bowel disease Researchers sought to determine the clinical characteristics of patients with both myocarditis and inflammatory bowel disease. Immunosuppression therapy may be beneficial ...
ARCHER is designed to assess the impact of CardiolRx™ on cardiac magnetic resonance imaging parameters that measure heart dysfunction and edema/fibrosis-key measurements used to predict prognosis in ...
Inflammation resulting from a viral infection has traditionally been thought to cause acute myocarditis, which can lead to fatal heart arrhythmias in otherwise healthy young adults. Now, a new study ...
Change in the primary endpoint of left ventricular (LV) extracellular volume (ECV) showed a notable improvement (p = 0.0538) favouring CardiolRx™ over placebo. Reduction in ECV was associated with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results